Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Immunity ; 54(8): 1807-1824.e14, 2021 08 10.
Article in English | MEDLINE | ID: mdl-34380064

ABSTRACT

The transcription factor forkhead box O1 (FOXO1), which instructs the dark zone program to direct germinal center (GC) polarity, is typically inactivated by phosphatidylinositol 3-kinase (PI3K) signals. Here, we investigated how FOXO1 mutations targeting this regulatory axis in GC-derived B cell non-Hodgkin lymphomas (B-NHLs) contribute to lymphomagenesis. Examination of primary B-NHL tissues revealed that FOXO1 mutations and PI3K pathway activity were not directly correlated. Human B cell lines bearing FOXO1 mutations exhibited hyperactivation of PI3K and Stress-activated protein kinase (SAPK)/Jun amino-terminal kinase (JNK) signaling, and increased cell survival under stress conditions as a result of alterations in FOXO1 transcriptional affinities and activation of transcriptional programs characteristic of GC-positive selection. When modeled in mice, FOXO1 mutations conferred competitive advantage to B cells in response to key T-dependent immune signals, disrupting GC homeostasis. FOXO1 mutant transcriptional signatures were prevalent in human B-NHL and predicted poor clinical outcomes. Thus, rather than enforcing FOXO1 constitutive activity, FOXO1 mutations enable co-option of GC-positive selection programs during the pathogenesis of GC-derived lymphomas.


Subject(s)
B-Lymphocytes/cytology , Forkhead Box Protein O1/genetics , Germinal Center/immunology , Lymphoma, B-Cell/pathology , Animals , B-Lymphocytes/immunology , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Line , Cell Proliferation/genetics , Cell Survival/genetics , Gene Expression Regulation/genetics , HEK293 Cells , Humans , Lymphoma, B-Cell/genetics , MAP Kinase Kinase 4/metabolism , Mice , Mice, Inbred C57BL , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/genetics , Signal Transduction/immunology
2.
Immunity ; 51(3): 535-547.e9, 2019 09 17.
Article in English | MEDLINE | ID: mdl-31519498

ABSTRACT

Inactivating mutations of the CREBBP and EP300 acetyltransferases are among the most common genetic alterations in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Here, we examined the relationship between these two enzymes in germinal center (GC) B cells, the normal counterpart of FL and DLBCL, and in lymphomagenesis by using conditional GC-directed deletion mouse models targeting Crebbp or Ep300. We found that CREBBP and EP300 modulate common as well as distinct transcriptional programs implicated in separate anatomic and functional GC compartments. Consistently, deletion of Ep300 but not Crebbp impaired the fitness of GC B cells in vivo. Combined loss of Crebbp and Ep300 completely abrogated GC formation, suggesting that these proteins partially compensate for each other through common transcriptional targets. This synthetic lethal interaction was retained in CREBBP-mutant DLBCL cells and could be pharmacologically targeted with selective small molecule inhibitors of CREBBP and EP300 function. These data provide proof-of-principle for the clinical development of EP300-specific inhibitors in FL and DLBCL.


Subject(s)
B-Lymphocytes/physiology , CREB-Binding Protein/genetics , E1A-Associated p300 Protein/genetics , Epigenesis, Genetic/genetics , Germinal Center/physiology , Lymphoma, Follicular/etiology , Lymphoma, Large B-Cell, Diffuse/genetics , Acetyltransferases/genetics , Animals , Cell Line , HEK293 Cells , Humans , Mice , Mice, Inbred C57BL , Sequence Deletion/genetics , Transcription, Genetic/genetics
3.
Nature ; 607(7920): 808-815, 2022 07.
Article in English | MEDLINE | ID: mdl-35794478

ABSTRACT

Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma and remains incurable in around 40% of patients. Efforts to sequence the coding genome identified several genes and pathways that are altered in this disease, including potential therapeutic targets1-5. However, the non-coding genome of DLBCL remains largely unexplored. Here we show that active super-enhancers are highly and specifically hypermutated in 92% of samples from individuals with DLBCL, display signatures of activation-induced cytidine deaminase activity, and are linked to genes that encode B cell developmental regulators and oncogenes. As evidence of oncogenic relevance, we show that the hypermutated super-enhancers linked to the BCL6, BCL2 and CXCR4 proto-oncogenes prevent the binding and transcriptional downregulation of the corresponding target gene by transcriptional repressors, including BLIMP1 (targeting BCL6) and the steroid receptor NR3C1 (targeting BCL2 and CXCR4). Genetic correction of selected mutations restored repressor DNA binding, downregulated target gene expression and led to the counter-selection of cells containing corrected alleles, indicating an oncogenic dependency on the super-enhancer mutations. This pervasive super-enhancer mutational mechanism reveals a major set of genetic lesions deregulating gene expression, which expands the involvement of known oncogenes in DLBCL pathogenesis and identifies new deregulated gene targets of therapeutic relevance.


Subject(s)
Enhancer Elements, Genetic , Gene Expression Regulation, Neoplastic , Lymphoma, Large B-Cell, Diffuse , Mutation , Oncogenes , Down-Regulation , Enhancer Elements, Genetic/genetics , Humans , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/metabolism , Oncogenes/genetics , Positive Regulatory Domain I-Binding Factor 1/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-6/genetics , Receptors, CXCR4/genetics , Receptors, Glucocorticoid/metabolism , Repressor Proteins/metabolism
4.
Proc Natl Acad Sci U S A ; 120(11): e2218330120, 2023 03 14.
Article in English | MEDLINE | ID: mdl-36893259

ABSTRACT

Heterozygous inactivating mutations of the KMT2D methyltransferase and the CREBBP acetyltransferase are among the most common genetic alterations in B cell lymphoma and co-occur in 40 to 60% of follicular lymphoma (FL) and 30% of EZB/C3 diffuse large B cell lymphoma (DLBCL) cases, suggesting they may be coselected. Here, we show that combined germinal center (GC)-specific haploinsufficiency of Crebbp and Kmt2d synergizes in vivo to promote the expansion of abnormally polarized GCs, a common preneoplastic event. These enzymes form a biochemical complex on select enhancers/superenhancers that are critical for the delivery of immune signals in the GC light zone and are only corrupted upon dual Crebbp/Kmt2d loss, both in mouse GC B cells and in human DLBCL. Moreover, CREBBP directly acetylates KMT2D in GC-derived B cells, and, consistently, its inactivation by FL/DLBCL-associated mutations abrogates its ability to catalyze KMT2D acetylation. Genetic and pharmacologic loss of CREBBP and the consequent decrease in KMT2D acetylation lead to reduced levels of H3K4me1, supporting a role for this posttranslational modification in modulating KMT2D activity. Our data identify a direct biochemical and functional interaction between CREBBP and KMT2D in the GC, with implications for their role as tumor suppressors in FL/DLBCL and for the development of precision medicine approaches targeting enhancer defects induced by their combined loss.


Subject(s)
Lymphoma, Follicular , Lymphoma, Large B-Cell, Diffuse , Animals , Humans , Mice , Acetylation , B-Lymphocytes/metabolism , CREB-Binding Protein/genetics , CREB-Binding Protein/metabolism , Germinal Center , Lymphoma, Follicular/genetics , Lymphoma, Follicular/metabolism , Lymphoma, Follicular/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Mutation , Protein Processing, Post-Translational
5.
Immunity ; 43(6): 1064-74, 2015 Dec 15.
Article in English | MEDLINE | ID: mdl-26620759

ABSTRACT

The pathways regulating formation of the germinal center (GC) dark zone (DZ) and light zone (LZ) are unknown. In this study we show that FOXO1 transcription factor expression was restricted to the GC DZ and was required for DZ formation, since its absence in mice led to the loss of DZ gene programs and the formation of LZ-only GCs. FOXO1-negative GC B cells displayed normal somatic hypermutation but defective affinity maturation and class switch recombination. The function of FOXO1 in sustaining the DZ program involved the trans-activation of the chemokine receptor CXCR4, and cooperation with the BCL6 transcription factor in the trans-repression of genes involved in immune activation, DNA repair, and plasma cell differentiation. These results also have implications for the role of FOXO1 in lymphomagenesis because they suggest that constitutive FOXO1 activity might be required for the oncogenic activity of deregulated BCL6 expression.


Subject(s)
B-Lymphocytes/immunology , Cell Differentiation/immunology , Forkhead Transcription Factors/immunology , Germinal Center/immunology , Animals , B-Lymphocytes/cytology , Chromatin Immunoprecipitation , Flow Cytometry , Fluorescent Antibody Technique , Forkhead Box Protein O1 , Germinal Center/cytology , Humans , Immunoglobulin Class Switching/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Polymerase Chain Reaction , Somatic Hypermutation, Immunoglobulin/immunology
7.
Proc Natl Acad Sci U S A ; 114(14): E2911-E2919, 2017 04 04.
Article in English | MEDLINE | ID: mdl-28314854

ABSTRACT

Activating mutations of NOTCH1 (a well-known oncogene in T-cell acute lymphoblastic leukemia) are present in ∼4-13% of chronic lymphocytic leukemia (CLL) cases, where they are associated with disease progression and chemorefractoriness. However, the specific role of NOTCH1 in leukemogenesis remains to be established. Here, we report that the active intracellular portion of NOTCH1 (ICN1) is detectable in ∼50% of peripheral blood CLL cases lacking gene mutations. We identify a "NOTCH1 gene-expression signature" in CLL cells, and show that this signature is significantly enriched in primary CLL cases expressing ICN1, independent of NOTCH1 mutation. NOTCH1 target genes include key regulators of B-cell proliferation, survival, and signal transduction. In particular, we show that NOTCH1 transactivates MYC via binding to B-cell-specific regulatory elements, thus implicating this oncogene in CLL development. These results significantly extend the role of NOTCH1 in CLL pathogenesis, and have direct implications for specific therapeutic targeting.


Subject(s)
B-Lymphocytes/physiology , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Receptor, Notch1/genetics , B-Lymphocytes/pathology , Cell Proliferation/genetics , Gene Expression Regulation, Leukemic , Genes, myc , Humans , Mutation , Receptor, Notch1/blood
8.
Blood ; 128(10): 1362-73, 2016 09 08.
Article in English | MEDLINE | ID: mdl-27335277

ABSTRACT

Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. By combining whole-exome sequencing, targeted sequencing of tumor-related genes, whole-transcriptome sequencing, and high-resolution single nucleotide polymorphism array analysis, we aimed at disclosing the pathways that are molecularly deregulated in NMZL and we compare the molecular profile of NMZL with that of SMZL. These analyses identified a distinctive pattern of nonsilent somatic lesions in NMZL. In 35 NMZL patients, 41 genes were found recurrently affected in ≥3 (9%) cases, including highly prevalent molecular lesions of MLL2 (also known as KMT2D; 34%), PTPRD (20%), NOTCH2 (20%), and KLF2 (17%). Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating cell growth, were enriched in NMZL across mature B-cell tumors, functionally caused the loss of the phosphatase activity of PTPRD, and were associated with cell-cycle transcriptional program deregulation and increased proliferation index in NMZL. Although NMZL shared with SMZL a common mutation profile, NMZL harbored PTPRD lesions that were otherwise absent in SMZL. Collectively, these findings provide new insights into the genetics of NMZL, identify PTPRD lesions as a novel marker for this lymphoma across mature B-cell tumors, and support the distinction of NMZL as an independent clinicopathologic entity within the current lymphoma classification.


Subject(s)
Biomarkers, Tumor/genetics , Exome/genetics , Lymphoma, B-Cell, Marginal Zone/genetics , Mutation/genetics , Receptor, Notch2/genetics , Receptor-Like Protein Tyrosine Phosphatases, Class 2/genetics , Splenic Neoplasms/genetics , High-Throughput Nucleotide Sequencing/methods , Humans , Lymphoma, B-Cell, Marginal Zone/pathology , Splenic Neoplasms/pathology
9.
Proc Natl Acad Sci U S A ; 111(22): 8185-90, 2014 Jun 03.
Article in English | MEDLINE | ID: mdl-24843176

ABSTRACT

Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), which originates from germinal center (GC) B cells and harbors translocations deregulating v-myc avian myelocytomatosis viral oncogene homolog (MYC). A comparative analysis of microRNAs expressed in normal and malignant GC B cells identified microRNA 28 (miR-28) as significantly down-regulated in BL, as well as in other GC-derived B-NHL. We show that reexpression of miR-28 impairs cell proliferation and clonogenic properties of BL cells by modulating several targets including MAD2 mitotic arrest deficient-like 1, MAD2L1, a component of the spindle checkpoint whose down-regulation is essential in mediating miR-28-induced proliferation arrest, and BCL2-associated athanogene, BAG1, an activator of the ERK pathway. We identify the oncogene MYC as a negative regulator of miR-28 expression, suggesting that its deregulation by chromosomal translocation in BL leads to miR-28 suppression. In addition, we show that miR-28 can inhibit MYC-induced transformation by directly targeting genes up-regulated by MYC. Overall, our data suggest that miR-28 acts as a tumor suppressor in BL and that its repression by MYC contributes to B-cell lymphomagenesis.


Subject(s)
Cell Proliferation , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/pathology , MicroRNAs/physiology , Adaptor Proteins, Signal Transducing/metabolism , B-Lymphocytes/physiology , Burkitt Lymphoma/genetics , Burkitt Lymphoma/pathology , Burkitt Lymphoma/physiopathology , Carcinogenesis , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , DNA-Binding Proteins/metabolism , Down-Regulation/physiology , Gene Expression Regulation, Neoplastic/physiology , Genes, myc/physiology , Germinal Center , Humans , Lymphoma, B-Cell/physiopathology , MAP Kinase Signaling System/physiology , Nuclear Proteins/metabolism , RNA Processing, Post-Transcriptional/physiology , Transcription Factors/metabolism , Transcriptome
10.
Blood ; 123(15): 2378-88, 2014 Apr 10.
Article in English | MEDLINE | ID: mdl-24550227

ABSTRACT

Fludarabine refractoriness (FR) represents an unsolved clinical problem of chronic lymphocytic leukemia (CLL) management. Although next-generation sequencing studies have led to the identification of a number of genes frequently mutated in FR-CLL, a comprehensive evaluation of the FR-CLL genome has not been reported. Toward this end, we studied 10 FR-CLLs by combining whole-exome sequencing and copy number aberration (CNA) analysis, which showed an average of 16.3 somatic mutations and 4 CNAs per sample. Screening of recurrently mutated genes in 48 additional FR-CLLs revealed that ~70% of FR-CLLs carry ≥1 mutation in genes previously associated with CLL clinical course, including TP53 (27.5%), NOTCH1 (24.1%), SF3B1 (18.9%), and BIRC3 (15.5%). In addition, this analysis showed that 10.3% of FR-CLL cases display mutations of the FAT1 gene, which encodes for a cadherin-like protein that negatively regulates Wnt signaling, consistent with a tumor suppressor role. The frequency of FAT1-mutated cases was significantly higher in FR-CLL than in unselected CLLs at diagnosis (10.3% vs 1.1%, P = .004), suggesting a role in the development of a high-risk phenotype. These findings have general implications for the mechanisms leading to FR and point to Wnt signaling as a potential therapeutic target in FR-CLL.


Subject(s)
Cadherins/genetics , Drug Resistance, Neoplasm/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Aged , DNA Mutational Analysis , Female , Genotype , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Male , Middle Aged , Mutation , Transcriptome
12.
Environ Microbiol ; 17(11): 4239-52, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25472545

ABSTRACT

Acaryochloris marina is a symbiotic species of cyanobacteria that is capable of utilizing far-red light. We report the characterization of the phages A-HIS1 and A-HIS2, capable of infecting Acaryochloris. Morphological characterization of these phages places them in the family Siphoviridae. However, molecular characterization reveals that they do not show genetic similarity with any known siphoviruses. While the phages do show synteny between each other, the nucleotide identity between the phages is low at 45-67%, suggesting they diverged from each other some time ago. The greatest number of genes shared with another phage (a myovirus infecting marine Synechococcus) was four. Unlike most other cyanophages and in common with the Siphoviridae infecting Synechococcus, no photosynthesis-related genes were found in the genome. CRISPR (clustered regularly interspaced short palindromic repeats) spacers from the host Acaryochloris had partial matches to sequences found within the phages, which is the first time CRISPRs have been reported in a cyanobacterial/cyanophage system. The phages also encode a homologue of the proteobacterial RNase T. The potential function of RNase T in the mark-up or digestion of crRNA hints at a novel mechanism for evading the host CRISPR system.


Subject(s)
Exoribonucleases/genetics , Genome, Viral/genetics , Siphoviridae/classification , Siphoviridae/genetics , Synechococcus/virology , Clustered Regularly Interspaced Short Palindromic Repeats/genetics , Genomics , Molecular Sequence Data , Proteomics , Siphoviridae/isolation & purification , Synechococcus/genetics , Synteny
13.
Blood ; 120(11): 2240-8, 2012 Sep 13.
Article in English | MEDLINE | ID: mdl-22740445

ABSTRACT

Germinal centers (GCs) are sites of B-cell clonal expansion, hypermutation, and selection. GCs are polarized into dark (DZ) and light zones (LZ), a distinction that is of key importance to GC selection. However, the difference between the B cells in each of these zones in humans remains unclear. We show that, as in mice, CXCR4 and CD83 can be used to distinguish human LZ and DZ cells. Using these markers, we show that LZ and DZ cells in mice and humans differ only in the expression of characteristic "activation" and "proliferation" programs, suggesting that these populations represent alternating states of a single-cell type rather than distinct differentiation stages. In addition, LZ/DZ transcriptional profiling shows that, with the exception of "molecular" Burkitt lymphomas, nearly all human B-cell malignancies closely resemble LZ cells, which has important implications for our understanding of the molecular programs of lymphomagenesis.


Subject(s)
Germinal Center/pathology , Lymphoma, B-Cell/pathology , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Burkitt Lymphoma/immunology , Burkitt Lymphoma/metabolism , Burkitt Lymphoma/pathology , Cells, Cultured , Child , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Germinal Center/immunology , Germinal Center/metabolism , Humans , Immunoglobulins/genetics , Immunoglobulins/metabolism , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymph Nodes/metabolism , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/metabolism , Male , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , Palatine Tonsil/immunology , Palatine Tonsil/metabolism , Palatine Tonsil/pathology , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , Species Specificity , CD83 Antigen
14.
Nat Commun ; 15(1): 7195, 2024 Aug 21.
Article in English | MEDLINE | ID: mdl-39179580

ABSTRACT

The myocyte enhancer factor 2B (MEF2B) transcription factor is frequently mutated in germinal center (GC)-derived B-cell lymphomas. Its ammino (N)-terminal mutations drive lymphomagenesis by escaping interaction with transcriptional repressors, while the function of carboxy (C)-terminal mutations remains to be elucidated. Here, we show that MEF2B C-tail is physiologically phosphorylated at specific residues and phosphorylation at serine (S)324 is impaired by lymphoma-associated mutations. Lack of phosphorylation at S324 enhances the interaction of MEF2B with the SWI/SNF chromatin remodeling complex, leading to higher transcriptional activity. In addition, these mutants show an increased protein stability due to impaired interaction with the CUL3/KLHL12 ubiquitin complex. Mice expressing a phosphorylation-deficient lymphoma-associated MEF2B mutant display GC enlargement and develop GC-derived lymphomas, when crossed with Bcl2 transgenic mice. These results unveil converging mechanisms of action for a diverse spectrum of MEF2B mutations, all leading to its dysregulation and GC B-cell lymphomagenesis.


Subject(s)
Lymphoma, B-Cell , MEF2 Transcription Factors , Mutation , Animals , Humans , Mice , B-Lymphocytes/metabolism , Cell Line, Tumor , Germinal Center/metabolism , HEK293 Cells , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/metabolism , Lymphoma, B-Cell/pathology , MEF2 Transcription Factors/metabolism , MEF2 Transcription Factors/genetics , Mice, Transgenic , Phosphorylation , Protein Stability , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics
15.
Blood ; 118(23): 6153-63, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-22012066

ABSTRACT

Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1 and CEBPA mutations define World Health Organization 2008 provisional entities accounting for approximately 60% of patients, but the remaining 40% are molecularly poorly characterized. Using whole-exome sequencing of one CN-AML patient lacking mutations in NPM1, CEBPA, FLT3-ITD, IDH1, and MLL-PTD, we newly identified a clonal somatic mutation in BCOR (BCL6 corepressor), a gene located on chromosome Xp11.4. Further analyses of 553 AML patients showed that BCOR mutations occurred in 3.8% of unselected CN-AML patients and represented a substantial fraction (17.1%) of CN-AML patients showing the same genotype as the AML index patient subjected to whole-exome sequencing. BCOR somatic mutations were: (1) disruptive events similar to the germline BCOR mutations causing the oculo-facio-cardio-dental genetic syndrome; (2) associated with decreased BCOR mRNA levels, absence of full-length BCOR, and absent or low expression of a truncated BCOR protein; (3) virtually mutually exclusive with NPM1 mutations; and (4) frequently associated with DNMT3A mutations, suggesting cooperativity among these genetic alterations. Finally, BCOR mutations tended to be associated with an inferior outcome in a cohort of 422 CN-AML patients (25.6% vs 56.7% overall survival at 2 years; P = .032). Our results for the first time implicate BCOR in CN-AML pathogenesis.


Subject(s)
Exome/genetics , Gene Expression Regulation, Leukemic/genetics , Genetic Testing/methods , Leukemia, Myeloid, Acute/genetics , Proto-Oncogene Proteins/genetics , Repressor Proteins/genetics , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cohort Studies , Core Binding Factor Alpha 2 Subunit/genetics , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA Methyltransferase 3A , Fatal Outcome , Female , Humans , Karyotyping , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/mortality , Male , Nuclear Proteins/genetics , Nucleophosmin , Proto-Oncogene Proteins/metabolism , Repressor Proteins/metabolism , Survival Analysis , fms-Like Tyrosine Kinase 3/genetics
16.
Brief Funct Genomics ; 22(1): 42-48, 2023 01 20.
Article in English | MEDLINE | ID: mdl-36412115

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with poor response to R-CHOP therapy due to remarkable heterogeneity. Based on gene expression, DLBCL cases were divided into two subtypes, i.e. ABC and GCB, where ABC subtype is associated with poor outcomes. Due to its association with clinical outcome, this classification, also known as cell-of-origin (COO), is an efficient way to predict the response to R-CHOP therapy. Previous COO classification methods have some shortcomings, e.g. limited number of samples in the training dataset. These shortcomings challenge the robustness of methods and make it difficult to implicate these methods at clinical level. To overcome the shortcomings of previous methods, we developed a deep learning-based classifier model on a cohort of 381 DLBCL patients using expression data of 20 genes. We implemented multilayer perceptron (MLP) to train deep learning-based classifier, named MLP-COO. MLP-COO achieved accuracy of 99.70% and 94.70% on training and testing datasets, respectively, with 10-fold cross-validation. We also assessed its performance on an independent dataset of 294 DLBCL patients. On independent dataset, we achieved an accuracy of 95.90% with MCC of 0.917. To show its broader applicability, we used this classifier to predict the clinical outcome using survival data from two large cohorts of DLBCL patients. In survival analysis, MLP-COO recapitulates the survival probabilities of DLBCL patients based on their COO in both cohorts. We anticipate that MLP-COO model developed in this study will benefit in the accurate COO prediction of DLBCL patients and their clinical outcomes.


Subject(s)
Deep Learning , Lymphoma, Large B-Cell, Diffuse , Humans , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/drug therapy , Rituximab/therapeutic use , Rituximab/genetics , Genetic Techniques , Cyclophosphamide/therapeutic use
17.
Mol Biol Evol ; 28(8): 2269-74, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21335340

ABSTRACT

DNA polymerase γ is a family A DNA polymerase responsible for the replication of mitochondrial DNA in eukaryotes. The origins of DNA polymerase γ have remained elusive because it is not present in any known bacterium, though it has been hypothesized that mitochondria may have inherited the enzyme by phage-mediated nonorthologous displacement. Here, we present an analysis of two full-length homologues of this gene, which were found in the genomes of two bacteriophages, which infect the chlorophyll-d containing cyanobacterium Acaryochloris marina. Phylogenetic analyses of these phage DNA polymerase γ proteins show that they branch deeply within the DNA polymerase γ clade and therefore share a common origin with their eukaryotic homologues. We also found homologues of these phage polymerases in the environmental Community Cyberinfrastructure for Advanced Microbial Ecology Research and Analysis (CAMERA) database, which fell in the same clade. An analysis of the CAMERA assemblies containing the environmental homologues together with the filter fraction metadata indicated some of these assemblies may be of bacterial origin. We also show that the phage-encoded DNA polymerase γ is highly transcribed as the phage genomes are replicated. These findings provide data that may assist in reconstructing the evolution of mitochondria.


Subject(s)
Bacteriophages/enzymology , Bacteriophages/genetics , DNA, Mitochondrial/genetics , DNA-Directed DNA Polymerase/genetics , Bacteriophages/classification , Cyanobacteria/virology , DNA-Directed DNA Polymerase/metabolism , Evolution, Molecular , Gene Expression Regulation, Viral , Genome, Viral , Phylogeny
18.
PLoS Comput Biol ; 6(2): e1000686, 2010 Feb 26.
Article in English | MEDLINE | ID: mdl-20195493

ABSTRACT

Many bacteria exhibit multicellular behaviour, with individuals within a colony coordinating their actions for communal benefit. One example of complex multicellular phenotypes is myxobacterial fruiting body formation, where thousands of cells aggregate into large three-dimensional structures, within which sporulation occurs. Here we describe a novel theoretical model, which uses Monte Carlo dynamics to simulate and explain multicellular development. The model captures multiple behaviours observed during fruiting, including the spontaneous formation of aggregation centres and the formation and dissolution of fruiting bodies. We show that a small number of physical properties in the model is sufficient to explain the most frequently documented population-level behaviours observed during development in Myxococcus xanthus.


Subject(s)
Cell Physiological Phenomena/physiology , Models, Biological , Myxococcus xanthus/physiology , Spores, Bacterial/growth & development , Algorithms , Computational Biology/methods , Computer Simulation , Gravitation , Monte Carlo Method , Signal Transduction , Thermodynamics
19.
Front Immunol ; 12: 818758, 2021.
Article in English | MEDLINE | ID: mdl-35095922

ABSTRACT

In response to T-cell-dependent antigens, mature B cells in the secondary lymphoid organs are stimulated to form germinal centers (GCs), which are histological structures deputed to antibody affinity maturation, a process associated with immunoglobulin gene editing by somatic hypermutation (SHM) and class switch recombination (CSR). GC B cells are heterogeneous and transition across multiple stages before being eliminated by apoptosis or committing to post-GC differentiation as memory B cells or plasma cells. In order to explore the dynamics of SHM and CSR during the GC reaction, we identified GC subpopulations by single-cell (sc) transcriptomics and analyzed the load of immunoglobulin variable (V) region mutations as well as the isotype class distribution in each subpopulation. The results showed that the large majority of GC B cells display a quantitatively similar mutational load in the V regions and analogous IGH isotype class distribution, except for the precursors of memory B cells (PreM) and plasma cells (PBL). PreM showed a bimodal pattern with about half of the cells displaying high V region germline identity and enrichment for unswitched IGH, while the rest of the cells carried a mutational load similar to the bulk of GC B cells and showed a switched isotype. PBL displayed a bias toward expression of IGHG and higher V region germline identity compared to the bulk of GC B cells. Genes implicated in SHM and CSR were significantly induced in specific GC subpopulations, consistent with the occurrence of SHM in dark zone cells and suggesting that CSR can occur within the GC.


Subject(s)
B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Gene Expression Profiling , Germinal Center/immunology , Single-Cell Analysis , Somatic Hypermutation, Immunoglobulin , Transcriptome , B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/metabolism , Computational Biology/methods , Gene Expression Profiling/methods , Germinal Center/cytology , Humans , Immunoglobulin Class Switching , Immunoglobulin Variable Region/genetics , Immunologic Memory/genetics , Plasma Cells/immunology , Plasma Cells/metabolism , Receptors, Antigen, B-Cell/genetics , Receptors, Antigen, B-Cell/metabolism , Signal Transduction , Single-Cell Analysis/methods
20.
J Exp Med ; 217(10)2020 10 05.
Article in English | MEDLINE | ID: mdl-32603407

ABSTRACT

In response to T cell-dependent antigens, mature B cells are stimulated to form germinal centers (GCs), the sites of B cell affinity maturation and the cell of origin (COO) of most B cell lymphomas. To explore the dynamics of GC B cell development beyond the known dark zone and light zone compartments, we performed single-cell (sc) transcriptomic analysis on human GC B cells and identified multiple functionally linked subpopulations, including the distinct precursors of memory B cells and plasma cells. The gene expression signatures associated with these GC subpopulations were effective in providing a sc-COO for ∼80% of diffuse large B cell lymphomas (DLBCLs) and identified novel prognostic subgroups of DLBCL.


Subject(s)
B-Lymphocytes/pathology , Germinal Center/pathology , Lymphoma/pathology , B-Lymphocytes/metabolism , Cell Lineage , Fluorescent Antibody Technique , Gene Expression Profiling , Germinal Center/metabolism , Humans , Lymphoma/metabolism , Single-Cell Analysis
SELECTION OF CITATIONS
SEARCH DETAIL